Endometriosis and menopausal health: An EMAS clinical guide

C Tamer Erel, Erel CT, Meletios P Nigledis, Nigdelis MP, Meletios P Nigdelis, Ozcivit Erkan IB, İpek Betül Özçivit Erkan, Ipek Betul Ozcivit Erkan, Dimitrios G Goulis, Goulis DG, Chedraui P, Peter Chedraui, Giannini A, Andrea Giannini, Kiesel L, Ludwig Kiesel, Nancy Phillips, Phillips N, Nancy J. Phillips, Simoncini T, Tommaso Simoncini, Eleni Armeni, Armeni E, Boban J, Judith Boban, Iuliana Ceauşu, Iuliana Ceausu, Ceausu I, Timothy Hillard, Hillard T, Irene Lambrinoudaki, Ιrene Lambrinoudaki, Lambrinoudaki I, Antonina Smetnik, A. A. Smetnik, Smetnik A, Marina Šprem Goldštajn, Goldstajn MS, Marina Sprem Goldstajn, Petra Stute, van Dijken D, Dorenda van Dijken, Rees M, Margaret Rees
Maturitas · 2025 · vol. 202 , pp. 108715 · doi:10.1016/j.maturitas.2025.108715 · PMID:40907339 · W4413914453
review OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This EMAS clinical guide addresses the complex relationship between endometriosis and menopausal health, offering insights for healthcare professionals.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Endometriosis is a common gynecological condition, and problems may persist or develop after the menopause. Endometriosis or its treatment in premenopausal women may lead to premature or early menopause. Thus, it is imperative that healthcare providers are appropriately trained in management of endometriosis at the menopause and beyond. AIM: To provide an evidence-based clinical guide for the assessment and management of menopausal health in women with a history of endometriosis. MATERIALS AND METHODS: Review of the literature and consensus of expert opinion. SUMMARY RECOMMENDATIONS: Surgery is the preferred option for managing symptomatic endometriosis after the menopause, as it should reduce pain, ensure an accurate diagnosis, and decrease risk of malignancy. Women with endometriosis may experience a spontaneous early menopause or surgically induced menopause. Endometriosis is also associated with an increased risk of cardiovascular disease, ovarian, breast, and thyroid cancers, as well as osteoporosis. Menopausal hormone therapy (MHT) is indicated for managing vasomotor and genitourinary symptoms and maintaining bone health. Continuous combined MHT may be safer than other forms in both hysterectomized and non-hysterectomized women with endometriosis as the risk of recurrence and malignant transformation of residual endometriosis may be reduced. Estrogen-only MHT should be avoided, even for women who have had a hysterectomy. For women not using MHT, alternative pharmacological treatments, such as neurokinin-3 receptor antagonists, should be considered for managing vasomotor symptoms. Additionally, antiresorptive and anabolic therapies, along with calcium and vitamin D supplementation, should be provided as indicated to ensure skeletal protection. If endometriosis recurs during MHT use and the patient is symptomatic, several management strategies may be employed: altering the regimen, discontinuation, and use of non-hormonal strategies. Herbal preparations should be avoided as their efficacy is uncertain and some may contain estrogenic compounds.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (6)

Source provenance

europepmc
last seen: 2026-07-25T06:15:30.875455+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-07-25T06:10:26.848937+00:00
License: CC0 · commercial use OK